Question 1

Can I get Ozempic for weight loss?

Accepted Answer

Not on label. Ozempic is FDA-approved only for type 2 diabetes and (since 2020) for reducing major cardiovascular events in adults with T2D and established CVD. The same molecule (semaglutide) at a higher 2.4 mg dose is sold as Wegovy for chronic weight management, and Zepbound (tirzepatide) carries a separate obesity indication. Prescribing Ozempic for weight loss without T2D is off-label and rarely covered by commercial insurance or Medicare. If obesity is the primary concern, Wegovy or Zepbound is the labeled option.

Question 2

Which has stronger data for obesity?

Accepted Answer

Zepbound, by a wide margin. SURMOUNT-1 (Jastreboff 2022 NEJM, PMID 35658024) showed tirzepatide 15 mg produced -20.9% TBWL at 72 weeks in adults with obesity without diabetes. SURMOUNT-5 (Aronne 2025 NEJM, PMID 40353578) is the only head-to-head obesity RCT and showed tirzepatide -20.2% vs semaglutide 2.4 mg -13.7% at 72 weeks. Ozempic itself has no obesity pivotal trial; its weight-loss data come from T2D trials at the lower 0.5-2 mg doses, where typical loss runs 4-7 kg.

Question 3

Why does my doctor switch me from Ozempic to Zepbound?

Accepted Answer

Three common reasons. First, magnitude: if weight loss is the dominant clinical goal and Ozempic-driven losses have plateaued or fallen short, tirzepatide's larger effect in SURMOUNT-5 is the evidence-based next step. Second, indication-matching: if a patient's T2D has improved and the diagnosis no longer drives insurance coverage, Zepbound's obesity indication may keep them on therapy. Third, cost: Zepbound's LillyDirect cash-pay tier ($349-$499/mo) gives uninsured patients a manufacturer-direct option Ozempic does not match.

Question 4

Are the side effects different?

Accepted Answer

Both share GI-dominant adverse events — nausea, diarrhea, constipation, vomiting — and both carry the same FDA boxed warning for thyroid C-cell tumors. In SURMOUNT-5, tirzepatide actually had lower nausea (29%) than semaglutide (44%), but discontinuation due to adverse events was modestly higher with tirzepatide (8% vs 6%). Real-world tolerability is comparable; titrate slowly with either drug to minimize GI symptoms.

Question 5

Which has better cardiovascular outcomes?

Accepted Answer

Ozempic, by a wide evidence margin. SUSTAIN-6 (Marso 2016 NEJM, PMID 27633186) randomized 3,297 T2D patients at high CV risk to semaglutide vs placebo and showed a 26% reduction in major adverse cardiovascular events (HR 0.74) over a median 2.1 years. Zepbound's dedicated CV outcomes trial (SURPASS-CVOT) is still enrolling and reads out in 2027 — until then, tirzepatide has no peer-reviewed MACE-reduction evidence.

Question 6

Which is cheaper without insurance?

Accepted Answer

Zepbound, for now. Lilly's LillyDirect program sells Zepbound vials at $349/mo (starter dose) or $499/mo (maintenance) for cash-pay patients. Ozempic has no comparable manufacturer cash-pay program; retail prices run roughly $998/mo at U.S. pharmacies. NovoCare savings cards are limited to commercially insured T2D patients and exclude cash payers and Medicare/Medicaid. If you're paying out of pocket, Zepbound is the manufacturer-direct option.

Field	Ozempic	Zepbound
FDA-approved indication	Type 2 diabetes; CV risk reduction in T2D + CVD	Chronic weight management; obstructive sleep apnea
Mechanism	GLP-1 receptor agonist	Dual GIP / GLP-1 receptor agonist
Weight loss (pivotal trial)	-4.5 to -6.5 kg / 30-40 wk (SUSTAIN program, 1-2 mg)	-20.9% TBWL / 72 wk (SURMOUNT-1, 15 mg)
Head-to-head obesity trial (SURMOUNT-5, 72 wk)	-13.7% body weight (semaglutide 2.4 mg)	-20.2% body weight (tirzepatide 15 mg)
Cardiovascular outcome	MACE -26% (SUSTAIN-6, 2016)	SURPASS-CVOT pending 2027
Dosing	Once-weekly subq 0.25-2.0 mg (4-step titration)	Once-weekly subq 2.5-15 mg (6-step titration)
Cash price (manufacturer direct)	~$998/mo retail (no manufacturer cash-pay program)	$349 starter / $499 maintenance via LillyDirect
Insurance coverage angle	Covered under T2D benefit (A1c >=6.5% + metformin trial)	Covered under obesity benefit (BMI >=30, or >=27 + comorbidity); often excluded

Ozempic vs Zepbound (2026): T2D Label vs Obesity Label

The verdict

Side-by-side comparison

Frequently asked questions